spacer
home > pmps > summer 2018 > connected health services and smart device solutions
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Connected Health Services and Smart Device Solutions

The market model for traditional pharmaceuticals, which is based on formulary positioning and prescriptions given by doctors, has been under pressure, giving rise to an end-user and consumer-driven approach. Additionally, changes in payment models have been linked to positive patient outcomes, otherwise known as ‘payment by results’.

For pharmaceuticals, the concept of patient centricity is a major trend, which – alongside more defined clinical/regulatory approaches, an increased number of biologic drugs, higher-drug specificity, and treatments linked to diagnostic data – is combining with a subsegmentation approach that concerns patients where drugs can be most effective. While efficacy and safety are still fundamental for gaining drug approval, also of importance is exploring and understanding the care journey provides valuable insight into the needs of stakeholders, as well as the basis for defining services that are essential for stakeholders and patients in subsegments. A service model that is dedicated to the drug will be able to meet individual and segment needs, including secondary disease measures, monitoring, and adherence and compliance services. Smooth interaction with stakeholders is critical for deriving value from this drug/ service differentiation. This change in the stakeholder/patient engagement equation evidences that bespoke connected health services are proving to be vital tools.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

RWS Life Sciences Welcomes New VP of Quality

RWS Life Sciences welcomes Clarice Streets, ASQ, CMQ, OE, as Vice President, Global Quality and Process, in charge of the strategic direction and implementation of its Quality system, underlying organizational processes, and change management.
More info >>

White Papers

R&D to Product: How to Reduce Costly Scale-Up Problems

Natoli Engineering Company, Inc.

When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
More info >>

 
Industry Events

SMi’s 9th Annual Biosimilars & Biobetters Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement